Northern Ireland to Offer Meningitis B Vaccine to All Year 14 Pupils and New University Students from July 31
Health authorities in Northern Ireland have announced a new vaccination programme that will offer a two-dose meningitis B vaccine to all Year 14 pupils and new university entrants under the age of 25, with the rollout beginning on 31 July 2026. The initiative, confirmed by the Public Health Agency and the Department of Health, represents a significant expansion of Northern Ireland's immunisation programme and is designed to protect young people at the age when they are statistically most vulnerable to meningococcal disease.
Background
Meningitis B, caused by the bacterium Neisseria meningitidis serogroup B, is the most common form of bacterial meningitis in the United Kingdom and Ireland. The disease can progress with terrifying speed — a person can go from feeling mildly unwell to being critically ill within hours — and even with prompt treatment, it carries a mortality rate of around 10%. Survivors frequently experience life-changing complications including hearing loss, limb amputation, and neurological damage. The impact on families and communities is profound, and the disease has long been a priority for public health authorities across these islands.
Young people aged 15 to 24 are at significantly elevated risk of meningococcal disease compared to the general population, a pattern that is particularly pronounced among those entering university or college for the first time. The reasons for this are well understood: young people in this age group are more likely to be living in close proximity to large numbers of peers, sharing accommodation, socialising in crowded environments, and encountering individuals from different geographic backgrounds who may carry strains of the bacterium to which they have no prior immunity. Freshers' week, in particular, has historically been associated with clusters of meningitis cases.
A meningitis B vaccine — Bexsero — has been available in the United Kingdom since 2015 and is already offered to infants as part of the routine childhood immunisation schedule. However, the protection conferred by the infant vaccine wanes over time, and there has been growing pressure from meningitis charities and public health experts to extend vaccination to the adolescent and young adult age groups. Northern Ireland's decision to do so from July 2026 follows similar moves in other parts of the UK and reflects the accumulating evidence base for the vaccine's effectiveness in this population.
Key Developments
The new programme, announced by the Public Health Agency on 16 July, will offer a two-dose course of the meningitis B vaccine to all Year 14 pupils — those in their final year of secondary school — and to all new university entrants under the age of 25. The rollout begins on 31 July, ahead of the new academic year, to ensure that as many eligible young people as possible are vaccinated before they enter the higher-risk environment of university or college life.
The vaccine will be administered through GP practices and school immunisation teams, with a catch-up programme available for those who miss the initial rollout. The Public Health Agency has confirmed that the programme is fully funded by the Department of Health and that there will be no cost to eligible individuals. Information packs are being sent to schools and universities across Northern Ireland, and a dedicated helpline has been established for parents and young people with questions about the programme.
Meningitis charities including Meningitis Now and the Meningitis Research Foundation have welcomed the announcement, describing it as a "life-saving" decision that will prevent deaths and serious disability among young people in Northern Ireland. The charities have been campaigning for the extension of meningitis B vaccination to this age group for several years.
Why It Matters
The introduction of meningitis B vaccination for Year 14 pupils and new university students is a genuinely significant public health intervention. Northern Ireland has historically had higher rates of meningococcal disease than many other parts of the UK, a pattern that has been attributed to a combination of demographic factors and the particular social mixing patterns of young people in the region. The decision to vaccinate ahead of the academic year is particularly important: the weeks around freshers' events are when the risk is highest, and ensuring that students are protected before they arrive on campus could prevent a number of cases each year. For context, England introduced a similar programme for university students in 2015, and the evidence from that rollout suggests a meaningful reduction in cases among the vaccinated cohort. Northern Ireland's programme, while later in coming, is comprehensive in its scope and should deliver comparable benefits.
Local Impact
The programme will be delivered through GP practices and school immunisation teams across all five health and social care trusts — Belfast, South Eastern, Southern, Western, and Northern. Queen's University Belfast and Ulster University, which together enrol tens of thousands of students each year, have confirmed they will work with the Public Health Agency to promote the programme to incoming students. The Students' Unions at both universities have welcomed the announcement and are planning information campaigns to encourage uptake. For families across Northern Ireland, the news will bring genuine reassurance — meningitis B is one of those diseases that parents fear disproportionately, and the knowledge that their children will be offered protection before heading to university will be a source of considerable comfort.
What's Next
The vaccination programme begins on 31 July, with GP practices contacting eligible patients directly. Schools will receive information packs before the end of the summer term, and the Public Health Agency will run a public awareness campaign throughout August to maximise uptake. The agency has set a target uptake rate of 75% for the first year of the programme, which it regards as achievable based on the experience of similar programmes elsewhere in the UK. A review of the programme's effectiveness will be conducted after the first academic year, with the results expected to be published in 2027.
